Melhem Solh, MD | Authors

Articles

Recommendations for Treating Patients With TP53-Mutated AML or MDS

February 06, 2023

Melhem Solh, MD, discusses the future for patients with myelodysplastic syndrome and acute myeloid leukemia that harbors a TP53 gene mutation, and gives his own recommendations to community oncologists who are treating patients with this disease.

Allogeneic SCT Shows Efficacy in TP53+ AML and MDS

December 15, 2022

Melhem M. Solh, MD, discusses results of a study investigating allogeneic stem cell transplant in patients with myelodysplastic syndrome and acute myeloid leukemia with a TP53 mutation, previously presented at the 2022 Transplantation & Cellular Therapy Meetings.